ORIGINAL RESEARCH article

Front. Oncol.

Sec. Cancer Epidemiology and Prevention

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1534682

Association of cumulative exposure to Chinese visceral adiposity index and gastrointestinal cancer: A Prospective Cohort Study

Provisionally accepted
Jiaxing  LiJiaxing Li1,2Wanchao  WangWanchao Wang2Chao  MaChao Ma1,2Kuan  LiuKuan Liu1,2Shuqing  CuiShuqing Cui1,3Yuan  TianYuan Tian2Zhigang  DongZhigang Dong2Wenqiang  WeiWenqiang Wei2Shouling  WuShouling Wu4Siqing  LiuSiqing Liu2*
  • 1School of Clinical Medicine, North China University of Science and Technology, Tangshan, Hebei Province, China
  • 2First Division of Hepatobiliary and Pancreatic Surgery,Affiliated Hospital of North China University of Science and Technology, Tangshan, China
  • 3Hepatobiliary Surgery,Affiliated Kailuan General Hospital of North China University of Science and Technology, Tangshan, China
  • 4Health Care Center, Affiliated Kailuan General Hospital of North China University of Science and Technology, Tangshan, China

The final, formatted version of the article will be published soon.

Background Using the Kailuan Cohort, we investigated the association between cumulative exposure to the Chinese visceral adiposity index (CVAI) and the risk of developing gastrointestinal (GI) cancers.Methods A prospective cohort study was conducted among participants who underwent three consecutive health examinations in the Kailuan Cohort from 2006 to 2010. Participants were categorized into quartiles based on their cumulative CVAI (cumCVAI). The cumulative incidence of GI cancers was estimated using Kaplan-Meier curves. The dose-response relationship between CVAI and the risk of developing GI cancers was examined using restricted cubic spline (RCS) in 2 multivariable adjusted models. Multivariate Cox proportional hazards regression analysis was performed to assess the association between cumCVAI quartiles and the incidence of GI cancers. Furthermore, subgroup analyses and sensitivity analyses were conducted.Results A total of 44,213 individuals were included in this study. The incidence rates of GI cancers per 1,000 person-years for the Q1 to Q4 groups were 1.00,1.45,1.62 and 2.11, respectively. The RCS curve demonstrated a significant dose-response relationship between cumCVAI and the occurrence of GI cancers events (P for overall trend < 0.001; P for nonlinear trend < 0.001). After adjusting for potential confounders, compared with the Q1 group, the risk of GI cancers was significantly elevated in the Q2 group (HR 1.26; 95% CI 1.01, 1.58), Q3 group (HR 1.31; 95% CI 1.05, 1.64), and Q4 group (HR 1.48; 95% CI 1.19, 1.85). This association was particularly evident in older individuals, females, those with a BMI ≥ 24 kg/m 2 , non-smokers, and non-drinkers.Our findings demonstrate a significant association between high cumCVAI and an increased incidence of GI cancers. Prolonged maintenance of CVAI within optimal levels may serve as a potential preventive strategy for GI cancers.

Keywords: Chinese visceral adiposity index, gastrointestinal cancer, visceral fat, visceral adipose tissue, cohort study

Received: 14 Feb 2025; Accepted: 16 Jun 2025.

Copyright: © 2025 Li, Wang, Ma, Liu, Cui, Tian, Dong, Wei, Wu and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Siqing Liu, First Division of Hepatobiliary and Pancreatic Surgery,Affiliated Hospital of North China University of Science and Technology, Tangshan, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.